July 2018
Volume 59, Issue 9
Open Access
ARVO Annual Meeting Abstract  |   July 2018
A Refillable Drug Delivery Device to the Retina
Author Affiliations & Notes
  • Nobuhiro Nagai
    Graduate School of Medicine, Tohoku University, Sendai, MIYAGI, Japan
  • Saaya Saijo
    Graduate School of Medicine, Tohoku University, Sendai, MIYAGI, Japan
  • Yuanhui Song
    Graduate School of Medicine, Tohoku University, Sendai, MIYAGI, Japan
  • Hirokazu Kaji
    Graduate School of Engineering, Tohoku University, Sendai, Japan
  • Matsuhiko Nishizawa
    Graduate School of Engineering, Tohoku University, Sendai, Japan
  • Toshiaki Abe
    Graduate School of Medicine, Tohoku University, Sendai, MIYAGI, Japan
  • Footnotes
    Commercial Relationships   Nobuhiro Nagai, Tohoku University (P); Saaya Saijo, Tohoku University (P); Yuanhui Song, None; Hirokazu Kaji, None; Matsuhiko Nishizawa, None; Toshiaki Abe, Tohoku University (P)
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science July 2018, Vol.59, 5704. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Nobuhiro Nagai, Saaya Saijo, Yuanhui Song, Hirokazu Kaji, Matsuhiko Nishizawa, Toshiaki Abe; A Refillable Drug Delivery Device to the Retina. Invest. Ophthalmol. Vis. Sci. 2018;59(9):5704.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To evaluate the ability of refilling the drug in vitro and in vivo and drug delivery to the retina of the device consisting of a silicone reservoir and an injectable gelatin/chitosan gel as a drug formulation.

Methods : The silicone reservoir was fabricated with polydimethylsiloxane using a computer-aided design and manufacturing to have micro-pores at a releasing side. The drug was injected and formulated in the reservoir by in situ crosslinking of gelatin/chitosan gel with 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide, hydrochloride. The in vitro release of fluorescein isothiocyanate–dextran 150 kDa (FD150) was studied. The in vivo release of FD150 in rabbits was evaluated by observing the cryosection of the eye and measuring the fluorescent intensity of retina homogenates 1 and 4 weeks after treatment.

Results : The in vitro release profile showed a constant release of FD150 with decreasing release rate for 4 weeks. After reinjecting the FD150-loaded gel in the reservoir, the same release profile as the first injection was observed. The in vivo study showed that FD150 was detected in the retina 1 and 4 weeks after treatment. The gel could be injected in the device implanted on the sclera.

Conclusions : The refillable drug delivery device is a promising tool to administer drug over the long lifetime of the device by reinjecting the drug.

This is an abstract that was submitted for the 2018 ARVO Annual Meeting, held in Honolulu, Hawaii, April 29 - May 3, 2018.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×